ABSTRACT

Background Interferon gamma release assays (IGRAs) are the first new diagnostic tests for latent tuberculosis (TB) infection (LTBI) since the century-old tuberculin skin test (TST). They are cell-mediated immune-based blood tests that have revolutionised LTBI diagnosis and are increasingly recommended by national guidelines.

Objectives With the rapid expansion of the IGRA evidence-base in recent years, the limitations of IGRA and uncertainties in clinical interpretation of IGRA results have increasingly come into focus. In LTBI diagnosis these include: prognostic power of IGRAs relative to TST for quantifying risk of progression to active disease, false-negative rates in immunocompromised patients, the clinical meaning of IGRA reversion and the significance of the size of IGRA response. Furthermore, the role of IGRAs in the diagnostic work-up of active TB is unclear, and there is little evidence supporting use of the tests in anti-TB treatment monitoring.

Methodological approach On-going large prospective longitudinal clinical endpoint cohort studies of active and latent TB will tackle some of the uncertainties, based on existing evidence.

Conclusions and impact Current and planned clinical research will fill the gaps in the evidence-base, narrowing the areas of uncertainty and informing future policy. Translational research into next-generation IGRAs and new T cell-based diagnostic platforms will likely overcome the limitations of current IGRAs in the near future.

INTRODUCTION

Mycobacterium tuberculosis (MtB) causes almost 9 million cases of active tuberculosis (TB) annually, resulting in over 1.4 million deaths; one-third of the world’s population is estimated to be latently infected. The incidence of TB in the UK has risen over the last two decades and, in line with most high-income countries, the majority of cases occur in foreign-born individuals from high-incidence nations.

Individuals with latent TB infection (LTBI) comprise a large reservoir from which future active cases arise, but chemoprophylactic treatment can effectively prevent subsequent development of active TB. Diagnosis and treatment of LTBI is therefore a cornerstone of TB control in high-income low-incidence countries. Since the risk of progressing to active TB is highest within the first 2–3 years following infection, this strategy specifically targets recently exposed individuals as well as those with risk factors for increased risk of progression to active TB, in particular HIV-associated or iatrogenic immunosuppression.

Until recently the diagnosis of LTBI was dependent on the tuberculin skin test (TST), which suffers from poor specificity (due to confounding by prior BCG vaccination) and low sensitivity in immunocompromised patients. Interferon-gamma release assays (IGRAs) are blood tests developed to improve diagnosis by measuring the ex vivo cellular immune response to MtB-specific antigens, and are commercially available as QuantiFERON®-TB Gold In-Tube (QFT-GIT) (Cellestis, Carnegie, Australia) and T-SPOT®.TB (Oxford Immunotec, Abingdon, UK). These tests are not confounded by prior BCG vaccination. A positive IGRA in someone with no clinical or radiological evidence of active TB thus constitutes a diagnosis of LTBI.

Published guidelines in most high-income low-incidence countries now recommend use of IGRAs in the diagnosis of MtB infection, either in a two-step testing strategy where the IGRA is used to confirm MtB infection in BCG-vaccinated persons who test positive by TST or as a single-step IGRA. However, there are several uncertainties in their clinical application and interpretation (table 1).

UNCERTAINTIES IN IGRA TESTING

Latent TB

The central challenge of treatment for LTBI is identifying those with the highest risk of progression. Since only approximately 5% of TST-positive TB contacts progress to active TB within 2–5 years of exposure, the number of TST-positive contacts requiring treatment to prevent one case of active TB (number needed to treat, NNT) is about 20. Given that the TB burden in low-incidence countries is largely driven by LTBI progressing to active disease, a more powerfully predictive test to stratify latently infected individuals by progression risk would improve targeting of preventive treatment thereby reducing the NNT.

Several longitudinal studies have confirmed that IGRAs predict progression from LTBI to active TB. However, their prognostic power compared with the TST has been a key area of uncertainty. One systematic review of 15 studies with 26 680 individuals concluded that the prognostic power of IGRAs and the TST were low and broadly equivalent, while another review of 28 studies including >30 000 individuals found IGRAs to be more predictive than the TST. Updated guidelines from the National Institute for Health and Clinical Excellence (NICE) on the use of IGRAs highlighted the paucity of high-quality studies of the...
A new study published in this issue of *Thorax* makes an important contribution to this evidence base and may help to inform IGRA-based screening policies. A single-step QFT-GIT screening strategy in 1769 recent TB contacts was evaluated in routine practice in Leicester, UK. Among untreated contacts, QFT-GIT had 70% sensitivity and 86% specificity for identifying LTBI progressing to active disease in 2 years, and the NNT of QFT-positive cases to prevent one case of active TB was 7, substantially lower than previously reported for the TST. This figure needs to be interpreted with caution, however, as it is lower than that reported by almost all previous studies and meta-analyses and may reflect inherent bias in the study design because the investigators making the diagnoses were not blinded to the IGRA results. Nonetheless, the study shows promise for the use of IGRA in contact investigations to improve targeting of preventive therapy. However, IGRA results were not predictive of progression to disease in older contacts (≥36 years), most likely due to a higher burden of infection that was remotely acquired (and therefore less likely to progress) in this mostly foreign-born population, analogous to the disappointing prognostic power of IGRA in high-burden countries.

Available longitudinal outcome data and the higher specificity of IGRA collectively suggest that the NNT for IGRA-positive contacts is lower than for TST-positive contacts, but most available evidence suggests it is still far from that required to effect a step change in TB control and prevention. Enhancing the prognostic power of IGRA, thereby reducing the NNT, is therefore an urgent research priority (box 1).

Since recently infected contacts are at higher risk of progression to active TB, a test able to distinguish recently acquired infection from remotely acquired infection would substantially reduce the NNT. Neither IGRA nor the TST are capable of this discrimination, and targeting recently infected persons will continue to depend on epidemiological risk factors until such a test is developed.

Some studies suggest that a larger size of baseline IGRA response may be predictive of progression, but there are currently insufficient data to use this clinically to risk-stratify, and more data correlating quantitative baseline responses with clinical outcomes are required (box 1). Therefore, results should currently only be interpreted in a binary fashion as positive or negative. Borderline results are uninterpretable and have no clinical significance, and should therefore be repeated. Indeterminate results, which usually result from a failed positive control and are more common in the setting of suppressed cellular immunity, are also uninterpretable and should also be repeated.

Where IGRA results are repeated, results may change from positive to negative or vice versa. Conversion from negative to positive has similar clinical implications to TST conversion, reflecting recent acquisition of infection. The clinical significance of reversion from positive to negative is uncertain, although it may reflect spontaneous clearance of infection and low/absent risk of progression. Only longitudinal clinical outcome studies will determine if this is the case (box 1).

**Active TB**

IGRAs measure a cellular immune response to *Mtb*-specific antigens. A positive result therefore indicates infection, but does not distinguish active from latent TB. Since *Mtb* infection is a prerequisite for TB disease, a negative IGRA result might provide a rapid ‘rule-out’ for active TB. However, this requires very high diagnostic sensitivity and, although IGRA may have higher sensitivity, it is still far from that required to effect a TST.

<table>
<thead>
<tr>
<th>Subgroups considered for IGRA testing by NICE</th>
<th>Uncertainties of IGRA</th>
</tr>
</thead>
<tbody>
<tr>
<td>New entrants from high incidence countries</td>
<td>Which immigrant subgroups to target?</td>
</tr>
<tr>
<td>Contacts of a TB outbreak</td>
<td>What is the meaning of reversion?</td>
</tr>
<tr>
<td>Healthcare workers</td>
<td></td>
</tr>
<tr>
<td>Adult contacts of active TB cases</td>
<td>False negative rates unknown in high-risk populations</td>
</tr>
<tr>
<td>Paediatric contacts of active TB cases*</td>
<td></td>
</tr>
<tr>
<td>Immunocompromised patients*</td>
<td></td>
</tr>
<tr>
<td>Active TB</td>
<td>False negative rates in 15–25%</td>
</tr>
<tr>
<td>Active and latent TB: effect of treatment†</td>
<td>Increased risk of false negative results</td>
</tr>
<tr>
<td></td>
<td>Unsuitable for treatment monitoring</td>
</tr>
</tbody>
</table>

* NICE recommends testing with both IGRA and the tuberculin skin test.
† NICE does not recommend IGRA testing but highlights potential uses which are the subject of further study.

IGRA, interferon gamma release assay; NICE, National Institute for Health and Clinical Excellence; TB, tuberculosis.

**Active TB: IDEA**

Clinical uncertainty: Clinical utility of IGRA in diagnostic work-up of active TB

Study design: Prospective longitudinal cohort

Population: NHS patients with suspected active TB

Intervention: Baseline IGRA

Outcome: Final diagnosis of active TB

Uncertainties addressed:
- Role of QFT-GIT vs T-SPOT®.TB vs TST
- If and where IGRA fit in diagnostic algorithm for evaluation of suspected active TB
- Cost-effectiveness of diagnostic strategies
- Role of next-generation IGRA in treatment monitoring
- Role of next-generation IGRA in rapidly ruling out suspected active TB
- Role of next-generation IGRA in treatment monitoring

**Latent TB: PREDICT**

Clinical uncertainty: Prognostic value of IGRA compared with the tuberculin skin test (TST) for predicting progression to active tuberculosis (TB)

Study design: Prospective longitudinal cohort

Population: New entrants and TB contacts

Intervention: Baseline IGRA

Outcome: Development of culture confirmed TB

Uncertainties addressed:
- Prognostic power of QFT-GIT vs T-SPOT®.TB vs TST
- Prognostic power of IGRA in high-risk populations including HIV-infected participants
- Prognostic power of quantitative baseline IGRA responses
- Clinical significance of IGRA reversion
- Improved prognostic power of next-generation IGRA

**Box 1 Current National Institute for Health Research Health Technology Assessment (NIHR HTA)-funded research addressing interferon-gamma release assay (IGRA) uncertainties**

**Latent TB: PREDICT**

Clinical uncertainty: Prognostic value of IGRA compared with the tuberculin skin test (TST) for predicting progression to active tuberculosis (TB)

Study design: Prospective longitudinal cohort

Population: New entrants and TB contacts

Intervention: Baseline IGRA

Outcome: Development of culture confirmed TB

Uncertainties addressed:
- Prognostic power of QFT-GIT vs T-SPOT®.TB vs TST
- Prognostic power of IGRA in high-risk populations including HIV-infected participants
- Prognostic power of quantitative baseline IGRA responses
- Clinical significance of IGRA reversion
- Improved prognostic power of next-generation IGRA

**Active TB: IDEA**

Clinical uncertainty: Clinical utility of IGRA in diagnostic work-up of active TB

Study design: Prospective longitudinal cohort

Population: NHS patients with suspected active TB

Intervention: Baseline IGRA

Outcome: Final diagnosis of active TB

Uncertainties addressed:
- Role of QFT-GIT vs T-SPOT®.TB vs TST
- If and where IGRA fit in diagnostic algorithm for evaluation of suspected active TB
- Cost-effectiveness of diagnostic strategies
- Role of next-generation IGRA in treatment monitoring
- Role of next-generation IGRA in rapidly ruling out suspected active TB
- Role of next-generation IGRA in treatment monitoring

**Box 1 Current National Institute for Health Research Health Technology Assessment (NIHR HTA)-funded research addressing interferon-gamma release assay (IGRA) uncertainties**

**Latent TB: PREDICT**

Clinical uncertainty: Prognostic value of IGRA compared with the tuberculin skin test (TST) for predicting progression to active tuberculosis (TB)

Study design: Prospective longitudinal cohort

Population: New entrants and TB contacts

Intervention: Baseline IGRA

Outcome: Development of culture confirmed TB

Uncertainties addressed:
- Prognostic power of QFT-GIT vs T-SPOT®.TB vs TST
- Prognostic power of IGRA in high-risk populations including HIV-infected participants
- Prognostic power of quantitative baseline IGRA responses
- Clinical significance of IGRA reversion
- Improved prognostic power of next-generation IGRA

**Active TB: IDEA**

Clinical uncertainty: Clinical utility of IGRA in diagnostic work-up of active TB

Study design: Prospective longitudinal cohort

Population: NHS patients with suspected active TB

Intervention: Baseline IGRA

Outcome: Final diagnosis of active TB

Uncertainties addressed:
- Role of QFT-GIT vs T-SPOT®.TB vs TST
- If and where IGRA fit in diagnostic algorithm for evaluation of suspected active TB
- Cost-effectiveness of diagnostic strategies
- Role of next-generation IGRA in treatment monitoring
- Role of next-generation IGRA in rapidly ruling out suspected active TB
- Role of next-generation IGRA in treatment monitoring

**Box 1 Current National Institute for Health Research Health Technology Assessment (NIHR HTA)-funded research addressing interferon-gamma release assay (IGRA) uncertainties**

**Latent TB: PREDICT**

Clinical uncertainty: Prognostic value of IGRA compared with the tuberculin skin test (TST) for predicting progression to active tuberculosis (TB)

Study design: Prospective longitudinal cohort

Population: New entrants and TB contacts

Intervention: Baseline IGRA

Outcome: Development of culture confirmed TB

Uncertainties addressed:
- Prognostic power of QFT-GIT vs T-SPOT®.TB vs TST
- Prognostic power of IGRA in high-risk populations including HIV-infected participants
- Prognostic power of quantitative baseline IGRA responses
- Clinical significance of IGRA reversion
- Improved prognostic power of next-generation IGRA

**Active TB: IDEA**

Clinical uncertainty: Clinical utility of IGRA in diagnostic work-up of active TB

Study design: Prospective longitudinal cohort

Population: NHS patients with suspected active TB

Intervention: Baseline IGRA

Outcome: Final diagnosis of active TB

Uncertainties addressed:
- Role of QFT-GIT vs T-SPOT®.TB vs TST
- If and where IGRA fit in diagnostic algorithm for evaluation of suspected active TB
- Cost-effectiveness of diagnostic strategies
- Role of next-generation IGRA in treatment monitoring
- Role of next-generation IGRA in rapidly ruling out suspected active TB
- Role of next-generation IGRA in treatment monitoring
sensitivity than the TST, neither is sensitive enough to exclude a
diagnosis of active TB.17 18

It is also proposed that a positive IGRA may provide a useful
adjunct to ‘rule-in’ the diagnosis in paediatric patients with a
clinical picture consistent with active TB, as the TST is already used.19
Furthermore, NICE guidelines suggest that TST/IGRA can be
beneficial in diagnosing cases where histological appearances are
not conclusive during the investigation of non-pulmonary TB.20
Clinical studies already indicate that next-generation IGRA,
incorporating additional Mtbc antigens or measuring additional
Mtbc-induced cytokines, provide significantly improved diagnostic
sensitivity (without compromising specificity) that could enable
rapid rule-out of suspected active TB (box 1).21 17 Newer T cell-
based diagnostic platforms utilise T cell functional signatures that
reflect mycobacterial burden to differentiate active from latent TB
and provide treatment monitoring tools.22–24

IS ONGOING RESEARCH LIKELY TO RESOLVE THE
UNCERTAINTIES?
The UK National Institute for Health Research Health
Technology Assessment Programme (NIHR HTA) UK Prognostic
Evaluation of Diagnostic IGRA ConsorTium (PREDICT) study is
a large cohort study in which 10 000 participants at high risk for
LTBI (TB contacts and new entrants from high-incidence coun-
tries) are undergoing IGRA and TST and are then being followed
up for 2–3 years to determine progression rates by baseline test
result. A wide range of novel biomarkers, including next-
generation IGRA, are also being assessed to correlate baseline
responses with clinical outcomes (box 1).

The NIHR HTA-funded IGRA in Diagnostic Evaluation of
Active TB (IDEA) study will assess the role of current and next-
generation IGRA in the diagnostic evaluation of 1012 patients
prospectively presenting with suspected active TB in routine
NHS practice (box 1). Evidence-based diagnostic algorithms and
care pathways will be developed and health economic analyses
performed to quantify the clinical utility and cost-effectiveness
of current and next-generation IGRA in the diagnostic assess-
ment of suspected active TB.

Additional studies to quantify and compare the predictive
value of IGRA include a European TBNET study currently
taking place using available routinely collected data in contacts
(http://www.tb-net.org/content/view/22/53/) and a large pros-
pective study, similar to PREDICT, planned by the US Centers
for Disease Control and Prevention.

WHAT SHOULD WE DO IN THE LIGHT OF UNCERTAINTY?
The current NICE guidelines10 20 take account of most of the
uncertainty around the prognostic power of existing IGRA
(table 1) and should be followed until other studies are com-
pleted. Given the paucity of evidence on the prognostic power of
IGRA in young children and immunocompromised indivi-
duals and the risk of false-negative results, concurrent IGRA
and TST are recommended by NICE in children aged <5 years
and HIV-positive individuals with a CD4 cell count of
<200 cells/mm3. IGRA should not be used in the diagnosis of
active TB until tests of higher sensitivity are available.5

CURRENT AND FUTURE POLICY
Given that >75% of the UK’s TB burden is carried by foreign-
born immigrants, and most of this is due to reactivation of LTBI
within the first several years after arrival, tackling imported
LTBI in new entrants is increasingly recognised as an attractive
strategy to reverse the relentless rise in UK TB rates.23–25 Policy
is evolving rapidly in this area in response to a growing evidence
base. For new entrant screening, NICE recommends using chest
x-rays and either the two-step TST with confirmatory IGRA or
single-step IGRA. NICE recently substantially broadened its
recommendations on which new entrants to screen from those
who originate from sub-Saharan Africa to all those from coun-
tries with a TB incidence of >40/100 000, which is lower than
some urban centres in the UK. Moreover, the requisite resources
to screen such a high proportion of all new entrants are not
available; overstretched TB services in parts of the UK with the
highest TB burdens often lack sufficient resources to screen any
new entrants.24

However, an intermediate screening threshold of TB incidence in the country of origin to preferentially target
migrant subgroups—such as those from the Indian subcontinent
and sub-Saharan Africa who are most likely to have LTBI—is
probably more cost-effective and pragmatic, as evidenced by a
recent multicentre UK study.27

A study published in the current issue of Thorax provides
further evidence to potentially inform policy on new entrant
screening.28 First, it compared the cost-effectiveness of TST and
each of the two IGRA platforms for new entrant screening
and found that single-step testing is more cost-effective than
two-step testing, particularly with QFT-GIT. Second, taken
in the two-step testing strategy to reverse the relentless rise in UK TB rates.25 Policy is

Competing interests
AL is inventor of several patents underlying T cell-based
diagnosis, including the ESAT-6/CFP-10 ELISPOT-based IGRA, T-SPOT®. TB which
was commercialised by a University of Oxford spin-out company, Oxford Immunotec
Ltd, in which the University of Oxford and AL have minority shareholdings and
royalty entitlements. AL’s research is independent of Oxford Immunotec Ltd, which
has no access to his research results and has never funded his research. All other
authors declare no support from any organisation for the submitted work, no
royalty entitlements. AL

Provenance and peer review
Not commissioned; internally peer reviewed.

REFERENCES
25th January 2013).
tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global
et al.


12 Hinks TSC, Dosanjh DPS, Innes JA, et al.


8 Rangaka MX, Wilkinson KA, Glynn JR, et al.


2 Whitworth HS, Scott M, Connell DW, et al. IGRAs - The gateway to T cell based TB diagnosis. Methods Published Online First: 3 Jan 2013. pii: S1046-2023(12)00326-X.


How should I interpret an interferon gamma release assay result for tuberculosis infection?
Ibrahim Abubakar, Helen Ruth Stagg, Hilary Whitworth and Ajit Lalvani

Thorax 2013 68: 298-301
doi: 10.1136/thoraxjnl-2013-203247

Updated information and services can be found at:
http://thorax.bmj.com/content/68/3/298

These include:

References
This article cites 23 articles, 8 of which you can access for free at:
http://thorax.bmj.com/content/68/3/298#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Epidemiologic studies (1829)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/